The Role of Immune Checkpoints in Lung Transplant (ILTRA)

Not yet recruitingOBSERVATIONAL
Enrollment

280

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Lung Transplant Rejection
Interventions
DIAGNOSTIC_TEST

Immune checkpoints analysis

The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.

DIAGNOSTIC_TEST

Gene expression analysis

Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2

Trial Locations (4)

10124

University of Turin, Torino

20122

Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan

35131

University of Padua, Padua

41121

University of Modena and Reggio Emilia, Modena

All Listed Sponsors
collaborator

University of Milan

OTHER

collaborator

University of Padova

OTHER

collaborator

University of Turin, Italy

OTHER

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER

NCT06302556 - The Role of Immune Checkpoints in Lung Transplant (ILTRA) | Biotech Hunter | Biotech Hunter